Claims should be based on clinically relevant ingredient dosages and supported by well-designed human studies that demonstrate the intended benefits in a relevant population and use context
Although ApoA-I plays a central role in reverse cholesterol transport, and contributes to anti-atherosclerotic activity through CEC, therapeutic drugs targeting ApoA-I have not yet to be applied clinically, so we look forward to future developments
Beyond transcriptional silencing via DNA methylation, post-transcriptional RNA modifications are emerging as an equally pivotal layer of epigenetic regulation
National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific statement
Additional regulations None Kansas Who can prescribe semaglutide